Treatment of Pituitary Gigantism With Persistent Disease After Surgery

Surgical resection does not always achieve full biochemical control in pituitary gigantism. When significant acromegaly symptoms persist postoperatively and there are no residual tumor mass effects, a structured adjuvant medical strategy is indicated to reach established hormonal targets.

This protocol applies to patients with persistent pituitary gigantism following surgery who continue to experience moderate to severe signs and symptoms of acromegaly in the absence of tumor mass effects — a setting that calls for initial adjuvant medical therapy rather than expectant management.

Therapeutic approach

Initial adjuvant medical therapy centres on a somatostatin analog — the specific agent selection, alternative options, and the criteria for switching depend on the full clinical picture detailed in the protocol.

Treatment targets: age-normalized serum IGF-1 and a random GH below 1.0 μg/L.

Complete regimen, sequencing decisions, and monitoring guidance are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/B978-0-12-814537-1.00002-6

Medical therapy recommended in patients with persistent disease following surgery.
Somatostatin analogs or pegvisomant recommended as initial adjuvant medical therapy in patients with significant disease, namely moderate to severe signs and symptoms of acromegaly but without tumor mass effects.
According to the 2014 Guidelines from the Endocrine Society, the main biochemical goals for treatment of acromegaly are an age-normalized serum IGF-1 value (disease control), a random GH , 1.0 µg/L (correlates with disease control), and to use the same hormonal assays throughout management.

View source ↗